pethidine hydrochloride Ampoules, injection 50 mg/ml, 100 mg/ml - 1 ml, 2 ml

This European pharmaceutical company specializes in the Central Nervous System (CNS) and Hospital Injectables. They operate in a niche market focusing on treatments for debilitating conditions like chronic pain and addiction. With a strong commitment to patient care, they are actively seeking new opportunities to expand their product portfolio and geographical reach, particularly within the EU market. Their core therapy areas include CNS disorders, pain management, and addiction treatment. The company has a robust research and development (R&D) program and actively seeks strategic partnerships to further its growth. This company develops and produces both prescription and over-the-counter (OTC) medications in various dosage forms, including injectables, solids, and liquids, which are manufactured under EU and other GMP standards. They hold numerous patents for their innovative drug formulations and have a track record of successful acquisitions, demonstrating their commitment to expanding their presence in the pharmaceutical industry. This company has a solid presence in the European market with an expansion into the Asia region, and is actively pursuing opportunities to expand its global footprint.